Caduet Indications/Uses

CADUET (amlodipine and atorvastatin) is indicated in patients for whom treatment with both amlodipine and atorvastatin is considered appropriate.
Hypertension: The amlodipine component is indicated for the first-line treatment of hypertension and can be used as the sole agent to control blood pressure (BP) in the majority of patients. Patients not adequately controlled on a single antihypertensive agent (other than amlodipine) may benefit from the addition of amlodipine component of amlodipine/atorvastatin, in the same manner as they would benefit from the addition of amlodipine alone.
Chronic Stable Angina: The amlodipine component is indicated for the first-line treatment of myocardial ischemia, whether due to fixed obstruction (stable angina) and/or vasospasm/vasoconstriction (Prinzmetal's or variant angina) of coronary vasculature. Amlodipine/atorvastatin may be used where the clinical presentation suggests a possible vasospastic/vasoconstrictive component but where vasospasm/vasoconstriction has not been confirmed. Amlodipine/atorvastatin may be used alone or in combination with other antianginal drugs in patients with angina that is refractory to nitrates and/or adequate doses of beta blockers.
Dyslipidemia: The atorvastatin component is indicated as an adjunct to diet for the treatment of patients with elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (apo B), and triglycerides (TG) and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial hypercholesterolemia), combined (mixed) hyperlipidemia (Fredrickson Types IIa and IIb), elevated serum TG levels (Fredrickson Type IV), and in patients with dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet.
The atorvastatin component is also indicated for the reduction of total C and LDL-C in patients with homozygous familial hypercholesterolemia (FH) when response to diet and other non-pharmacological measures are inadequate.
Prevention of Cardiovascular Disease (CVD): In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low high-density lipoprotein cholesterol (HDL-C), or a family history of early coronary heart disease, atorvastatin is indicated to: Reduce the risk of myocardial infarction (MI); Reduce the risk of stroke; Reduce the risk for Revascularization procedures and angina.
In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, atorvastatin is indicated to: Reduce the risk of myocardial infarction; Reduce the risk of stroke.
In adult patients with clinically evident coronary heart disease, atorvastatin is indicated to: Reduce the risk of non-fatal myocardial infarction, Reduce the risk of fatal and non-fatal stroke, Reduce the risk for revascularization procedures, Reduce the risk of hospitalization for congestive heart failure (CHF), Reduce the risk of angina.